|
AIDA v4 current version | AIDA v4.5 (and later) future versions |
|
Model building/structure | New features |
(i) Interconnected insulin-glucose submodels | (i) Comprehensive insulin/glucose model built from unit processes (diabetes “lego”-land) |
(ii) Empirical models for insulin/glucose dynamics and control | (ii) Physiologically based model of insulin absorption (generic) and kinetics |
(iii) Linear insulin disposition/elimination (superposition principle applies) | (iii) Fewer (only necessary and realistic) assumptions |
(iv) Use of fictive compartment (“active” insulin) | (iv) Patient specification with minimal number of identifiable parameters |
(v) Over parameterisation of patients (use of nonidentifiable parameters such as separate hepatic and peripheral insulin sensitivities) | (v) Specification of typical patient types (insulin sensitive versus resistant, etc.) parameterised accordingly |
|
Limitations | Overcoming limitations |
(i) IDDM only | (i) Both IDDM and NIDDM |
(ii) No insulin analogues | (ii) Both rapidly acting and very long-acting insulin analogues added |
(iii) Insulin dose ≤40 units | (iii) Insulin dose ≤60 units |
(iv) Carbohydrate intake/meal ≤80 g | (iv) Carbohydrate intake/meal ≤120 g |
(v) Oral hypoglycaemic drugs not incorporated | (v) Different types of oral hypoglycaemic drugs included |
(vi) Lifestyle events/effects not included (stress, physical activity, menstrual cycle, etc.) | (vi) Lifestyle events (stress, physical activity, menstrual cycle, etc.) included |
|
Technical | New features |
(i) Menu driven data entry (nongraphical) | (i) Intuitive graphical user interface |
|